Techcare Corp. ("Techcare" or the "Company"), formally known as BreedIT Corp. ("BreedIt"), was incorporated under the laws of the State of Delaware on May 26, 2010. The Company's common stock is traded in the United States on the OTCQB Market under the ticker symbol "TECR".

On February 8, 2016, the Company signed a Merger Agreement with Novomic Ltd. ("Novomic"), a private company incorporated under the laws of the state of Israel. The closing of the merger took place on August 9, 2016 pursuant to which Novomic became a wholly-owned subsidiary of the Company. The merger was structured as a reverse merger.

During the six months period ended June 30, 2017, the Company had a comprehensive loss of $3.1 million. As of June 30, 2017, the Company had accumulated losses of approximately $6.8 million. Based on the projected cash flows and Company's cash balances as of June 30, 2017, the Company's management is of the opinion that without further fund raising it will not have sufficient resources to enable it to continue advancing its activities including the development, manufacturing and marketing of its products for a period of at least 12 months from the date of issuance of these financial statements. As a result, there is substantial doubt about the Company's ability to continue as a going concern.

Management's plans include the continued commercialization of their products, continue taking cost reduction steps and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to reduce activities, curtail or cease operations. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The accounting policies adopted are consistent with those of the previous financial year.

The accompanying unaudited condensed consolidated financial statements and condensed footnotes have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for fair statement of results for the interim periods presented have been included. The results of operations for the six and the three months ended June 30, 2017 are not necessarily indicative of the results to be expected for the year or for other interim periods or for future years. The consolidated balance sheet as of December 31, 2016 is derived from audited financial statements as of that date; however, it does not include all of the information and footnotes required by GAAP for complete financial statements. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the SEC on May 10, 2017.

The accompanying consolidated financial statements include the accounts of Techcare, and its subsidiary, Novomic. All intercompany accounts and transactions have been eliminated in consolidation.

In March 2016, the FASB issued an ASU No. 2016-09, which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. The ASU is effective for annual reporting periods (including interim periods within those annual reporting periods) beginning after December 15, 2016 and all amendments of the ASU that apply must be adopted in the same period. The adoption by the Company of ASU No. 2016-09 on January 1, 2017, did not have any effect on the Company's consolidated financial statements.

NOTE 3: RESTATEMENT

The Company restated the March 31, 2016 financial statements in order to include additional accrued expenses that were not recorded in the previously reported period.

During the six months ended June 30, 2017 the Company entered into several agreements, under which the Company raised an aggregate amount of $800,000 as further detailed below:

In addition, during the second quarter of 2017, the Company entered into agreements with certain investors to issue 162,008 shares of common stock of the Company at a purchase price of $0.483 per share for a total consideration of $78,250. In July 2017, the Company received $28,250 on account of the transaction.

In the first quarter of 2017, the Company signed an agreement to issue 300,000 restricted shares of common stock of the Company to a service provider for his consulting services for a term of 18 months. As part of the consulting agreement, the Company also granted the service provider warrants exercisable to purchase 100,000 of the Company's common stock at an exercise price of $1.50 per warrant share exercisable for a period of 24 months commencing the date of the agreement. The total value of the agreement at the date of grant was $146,031.

In the second quarter of 2017, the Company signed a service agreement with a service provider pursuant to which the Company will pay a monthly fee and also granted the service provider 70,000 common stock which were issued in April 2017.

In the second quarter of 2017, the Company signed a consulting agreement with a service provider pursuant to which the Company will pay a monthly fee and will grant the service provider an option to purchase up to 500,000 common stock of the Company, issued as follows: (1) 50,000 common stock on the execution of the agreement, (2) the remaining 450,000 common stock shall be contingent upon the successful achievement of certain milestones, as described in the agreement. As of June 30, 2017 the Company had not yet issued the stock and, therefore, recorded a stock payable in the amount of $30,000 in the consolidated financial statements.

Stock based awards are accounted for using the fair value method in accordance with ASC 718, Shared Based Payment. The Company's primary type of stock based compensation consists of stock options to directors, employees, officers, consultants, and advisors. The Company uses the Black-Scholes option pricing model in valuing options.

During March 2017, the Company granted to certain employees options to purchase 723,027 of the Company's common stock and to non-employees options to purchase 2,000,952 of the Company's common stock for an exercise price of $0.0001. Out of all the option grants, 1,298,737 options were granted to related parties.

A summary of the stock option activity for the six-month period ended June 30, 2017:

The options granted during the six months period ended in June 30, 2017 were fully vested on the grant date and exercisable for 2.5 - 5 years. The following assumptions were applied in determining the options' fair value on their grant date:

The Company based the risk-free interest rate on the U.S. Treasury yield curve. The expected term in years represents the period of time that the awards granted are expected to be outstanding. The assumption for dividend yield is zero because the Company has not historically paid dividends nor does it expect to do so in the foreseeable future. The volatility was based on the historical stock volatility of several peer companies, as the Company has limited trading history to use the volatility of its own common stock. Stock-based compensation expense included in the Company's statements of operations were allocated as follows:

On June 23, 2017, the Company entered into an OEM agreement (the "Agreement") with a medical device and wellness applications company based in the United States (the "OEM Distributor"), according to which the Distributor will manufacture, distribute and sell the Company's Novokid head lice treatment products, in the US, Canada, Brazil, Argentina, Costa Rica and Colombia, all on an exclusive basis, pursuant to and in accordance with the terms and conditions set forth in the Agreement. As part of the Agreement, the OEM Distributor paid a royalty advance of $10,000 and also an amount of $140,000 which is held in an escrow account, until the Company completes certain milestones, as described in the Agreement.

Also, as part of the Agreement, the Company granted the OEM Distributor an option to purchase up to 9.09% of the Company's common stock for a total consideration of up to $900,000, exercisable until January 15, 2018. The fair value of the option amounted to $276,150. The key assumptions in the valuation of the option was as follows:

The Company and its subsidiary are taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.

b. Carryforward Tax Losses

As of June 30, 2017 and December 31, 2016, the Subsidiary had net operating carry forward tax losses of approximately $1.5 million and $0.9 million, respectively. A full valuation allowance was created against these carry forward tax losses since the realization of any future benefit from these net operating losses cannot be sufficiently assured at June 30, 2017 and December 31, 2016.

The corporate tax rate in Israel was 26.5% in 2015 and 25% in 2016. The regular corporate tax rate starting January 1, 2017 is 24% and starting January 1, 2018 will be 23%. The corporate tax rate in the U.S is approximately 35%.

Loss per share is based on the loss that is attributed to the stockholders holding common stock, divided by the weighted average number of common stock in issue during the period.

For purposes of the calculation of the diluted loss per share, the Company adjusts the loss that is attributed to the holders of the Company's common stock, and the weighted average number of common stock assuming conversion of all of the dilutive potential stock. The potential stock are taken into account only if their effect is dilutive (increases loss per share).

The carrying amount of the Company's financial instruments, including cash equivalents, current assets, accounts payable and accrued liabilities and notes payables approximate their fair value, due to their short term in nature and their carrying amounts approximates the amounts expected to be received or paid.

A hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The Company accounts for option liability as Level 3 since its inputs are unobservable inputs for the liability.

The following table is a reconciliation of the change for the financial liability where fair value measurement is estimated utilizing Level 3 inputs:

For the issuance of Common stock to the Company's Chairman of the board's affiliated entity, other related parties and option grants to the Company's directors, refer to note 4.

On February 22, 2017, the Company signed an amendment to the original service agreement with Zvi Yemini, the Company's chairman of the board and his affiliated entity-"Y.M.Y". According to the amendment, Mr. Yemini's monthly payment was increased to 45,000 NIS (approximately $12 thousands) starting February 2017.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION. Back to Table of Contents

FORWARD-LOOKING STATEMENTS

The following plan of operation provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Certain statements that the Company may make from time to time, including all statements contained in this Form 10-Q that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the safe harbor provisions set forth in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should," and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new product launches, market position and expenditures. The Company assumes no obligation to update any forward-looking statements. Additional information concerning factors which could cause differences between forward-looking statements and future actual results is discussed under the heading "Risk Factors" in the Company's Annual report on Form 10-K as filed with the SEC on May 10, 2017. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to help you understand our historical results of operations during the periods presented and our financial condition for the periods ended June 30, 2017 and 2016. This MD&A should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements for the years ended December 31, 2016 and 2015.

We are a technology company engaged in the design, development and commercialization of a delivery platform utilizing proprietary cold vaporization technology to enable a wide variety of health, wellness and beauty treatments (the "Platform").

We anticipate to commence generating revenues from the sale of Novokid, our head lice treatment platform during Q4/2017, following its receipt of regulatory approval from the CE (the European Union), which is anticipated to occur during Q3/2017, which will permit us to commence sales and marketing activities in Europe.

Before we enter the U.S. market, we will need to secure approval from the FDA (US Food and Drug Administration). Pursuant to our OEM Distribution agreement signed in June 2017 with a medical device and wellness applications company based in the United States (the "OEM Distributor"), The OEM Distributor will be solely responsible for obtaining and maintain the FDA approval and shell bear all costs related to such approval. We are a company with limited operations and no revenues from our business operations. There is substantial doubt that we can continue as a going concern for the next twelve months without the success of our new business operations.

We project that we will need to raise approximately $1,200,000 during the next 12 months in order to successfully implement our business plan and to become profitable, of which there can be no assurance. Failure to obtain this necessary capital at acceptable terms, if at all, when needed, may force us to delay, limit, or terminate our product development efforts and secure regulatory approvals and would adversely impact our planned research and development efforts in connection with the Company's future products, which may make it more difficult for us to attain profitability.

Our current and future products are all based on our device (the Device) which was developed over a period of 7 years. During the past 18 months, we have achieved the following:

During the next 12-18 months, we plan to focus our efforts on the following:

We may be required to obtain additional regulatory approvals for our head lice treatment platform and any future products. If unable to receive regulatory approval or commercialize our product candidates, our business will be adversely affected. CE approval is required for the marketing, distributing and sale of our products in the EU, whereas FDA approval is required for such marketing, distributing and sale in the US. In the event the products are to be sold in certain territories requiring additional regulatory approvals, such approvals will be obtained by us and/or by our distributors.

Parents and children exposed to head lice are now forced to use standard Over the Counter treatments that are toxic, often ineffective, time consuming and expensive. The global market for head lice treatments is estimated at $1.8 billion per annum whereas 6-12 million children get head lice each year in the US alone causing indirect damages estimated at $4-8 billion per annum. According to the Journal of Medical Entomology, 98% of lice have developed resistance to existing treatments in the US and they have now referred to as "super-lice". Most current treatments contain pesticides, alcohol or silicone, which are all associated with a wide variety of hazardous side effects. Novokid is a non-pesticide, natural, plant-based and eco-friendly solution that eliminates lice and super lice by a 10 minute dry treatment. This compares with current treatments that required 20-40 minutes of shampooing and daily combing. Our treatment is fast, dry, clean, and easily administered at home or on the go. Novokid can also be used as a maintenance and preventative treatment if used regularly.

Shine uses cold vaporization and a proprietary formulation to clean, treat and improve the appearance of the hair and scalp. In addition to removing the residue of products, the treatments will balance the hair's pH levels, add body and shine, define curls, and strengthen and protect hair from further damage. Like our solution for lice, users simply put a Shine capsule in the compressor, place the attached cap on their head and sit for a 10-minute treatment. There is no need to rinse or shampoo following the treatment.

The global hair care market is estimated to be in excess of $80 billion per annum, and we are looking to establish a presence in the hair salon and home treatment niche. To that end, we are in the process of expanding the Shine treatment product line to include formulations for the needs of specific hair types, such as dry, curly, colored, and over-processed hair.　

While the vaporizer for both Novokid and Shine is designated to be a one-time purchase, the Head Cap, and especially the capsules, will be sold separately based on the razor/razor-blade business model and based on our estimates, which we believe are both reasonable and conservative, our target customers are expected to purchase between 12-16 capsule units per year. Therefore, we estimate that the majority of the revenues that the Company will generate in the future will be based on capsules sales for both Novokid and Shine products.

The Company plans to focus its initial sales and marketing efforts on two of the largest markets in the world - the EU and US markets, starting in the EU where regulatory approval is expected in Q3/2017.

In order to achieve its intended global footprint and market presence, the Company's primary distribution method will be based on the B2B OEM and distribution models. We believe that these models will reduce our sales and marketing costs to a minimum while starting to generate revenues to support our R&D efforts for utilizing our technological platform to expand our product line.

Due to the importance of patents, the Company has devoted significant efforts and resources and will continue to invest resources in strengthening its patent portfolio. Below is the list of patents registered by the Company to date:

*Under approval process

The Company plans to expand existing patents related to pushing air using its vaporizer and new substances which are now being researched and documented, and more subjects that will be developed during research.

We spent approximately $1.5 million on R&D during the past two years. During this period, the Company completed the product development of both Novokid and Shine, which included finalization of commercial design of compressor, capsules and head cap and optimizing the products efficiency.

The Company plans to build upon the R&D achievements it had with the completion of the head lice treatment product as the basis to expand its variety of treatments and solutions, which will also be based on the developed platform and the knowledge the Company gained principally during the past two years.　

During the six months ended June 30, 2017 and 2016, we generated no revenues.

Our research and development expenses during the six months ended June 30, 2017 were $801,613, comprised of $332,514 of ongoing R&D expenses (compared to $478,634 during the same period in the prior year) and additional sum of $469,099 in stock based compensation to the Company's R&D employees and service providers.

During the six months ended June 30, 2017, we recorded fair value option expenses related to the distribution agreement with the US Distributor in June 2017.

Our general and administrative expenses during the six months ended June 30, 2017 were $2,020,014 (compared to $92,164 during the same period in the prior year) comprised of $446,153 of payroll and service providers' consultancy (compared to $92,164 during the same period in the prior year) and additional sum of $1,573,861 in stock based compensation to our management, consultants and service providers.

During the six months ended June 30, 2017, we incurred a net loss of $3,083,434. Excluding a sum of $2,042,960 in stock based compensation we incurred a net loss of $1,040,474 (compared to a net loss of $571,527 in the same period in the prior year) principally for the reasons noted above.

During the three months ended June 30, 2017 and 2016, we generated no revenues.

Our research and development expenses during the three months ended June 30, 2017 were $239,438 compared to $168,530 during the same period in the prior year. The increase is mainly due to ongoing R&D expenses related to Shine.

During the three months ended June 30, 2017, we recorded fair value option expenses related to the distribution agreement with the US OEM Distributor in June 2017.

Our general and administrative expenses during the three months ended June 30, 2017 were $171,088 compared to $64,276 during the same period in the prior year. The increase is mainly due to increase in professional services related to service providers' consultancy.

We incurred a net loss of $682,448 during the three months ended June 30, 2017 compared to a net loss of $233,373 in the same period in the prior year due principally for the reasons noted above.

Our balance sheet as of June 30, 2017 reflects total assets of $602,362 consisting mainly of cash of $297,609, other receivables of $178,581 and property and equipment net, of $105,674. As of December 31, 2016, the balance sheet reflects total assets of $410,609 consisting mainly of cash of $275,041, other receivables of $23,069 and property and equipment net, of $100,841.The increase is related mainly to issuance of common stock that increased our cash balances by $22,568 and an increase in other receivables by $155,512.

As of June 30, 2017, we had total current liabilities of $468,888 consisting of accounts payable and accrued expenses of $104,723, notes payable of $88,015 and option liability of $276,150. As of December 31, 2016, we had total current liabilities of $283,988 consisting of $203,962 in accounts payable and accrued expenses and $80,026 in notes payable. The increase is mainly due to option liability recorded as part of the OEM distribution agreement offset by payment of certain accounts payable and accrued expenses balances.

As of June 30, 2017, we had positive working capital of $7,302 compared to positive working capital of $14,122 at December 31, 2016. The working capital has been sufficient to sustain our operations to date, although there is substantial doubt about our ability to continue as going concern. Our total liabilities as of June 30, 2017 were $488,448 compared to $296,651 at December 31, 2016.

During the six months ended June 30, 2017, we used $775,512 of cash in our operating activities. This resulted mainly from an overall net loss of $3,083,434, offset by stock-based compensation expenses of $2,042,960, fair value option of $276,150 and a decrease in accounts payable and accrued expenses of $94,548.

During the six months ended June 30, 2016, we used $575,906 in our operating activities. This resulted mainly from a net loss of $571,527 and an increase in other receivables of $8,726.

During the six months ended June 30, 2017, we used $11,821 in our investing activities as compared to $26,013 in the same period in the prior year. The decrease was mainly due to a decrease in the purchase of fixed assets partially offset by an increase in long-term deposit.

During the six months ended June 30, 2017, our financing activities provided us with $800,000 through the issuance of common stock as compared to $413,245 in the same period in the prior year, out of which $165,000 were in proceeds from the issuance of common stock and $248,245 were in proceeds of funds on account of reverse merger.

While management believes the Company will be successful in its current and planned operating activities, there can be no assurance that the Company will be successful in the achievement of sales of its products that will generate sufficient revenues to earn a profit and sustain the operations of the Company.

Our ability to create sufficient working capital to sustain us over the next twelve-month period and beyond, is dependent on our ability to raise additional funds through the issuance of equity or debt instrument.

There can be no assurance that sufficient capital will be available to us. We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources, other than signed agreements that we expect to receive all funds and issue the stock during the third quarter of 2017.

As result of the above, there is substantial doubt about our ability to continue as a going concern. Our financial statements contain additional note disclosures with respect to this matter, but no accounting adjustments that relate to this matter.

We have no off-balance sheet arrangements.

There was no change to our critical accounting policies since the year ended December 31, 2016.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

None.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures.

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer (who is the Company's principal executive officer) and the Company's Chief Financial Officer, (who is the Company's principal financial officer) to allow for timely decisions regarding required disclosure. In designing and evaluating the Company's disclosure controls and procedures, the Company's management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and the Company's management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. The ineffectiveness of the Company's disclosure controls and procedures was due to material weaknesses identified in the Company's internal control over financial reporting as described below.

Management is responsible for establishing and maintaining adequate internal control over the Company's financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002, our management, with the participation of the Company's principal executive officer and principal financial officer has conducted an assessment, including testing, using the criteria in Internal Control - Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO") (2013). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. This assessment included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Based on this evaluation, the Company's management concluded its internal control over financial reporting was not effective and required improvement as of June 30, 2017. The ineffectiveness of the Company's internal control over financial reporting was due to the following material weaknesses:

(i) Inadequate segregation of duties consistent with control objectives; and

(ii) Ineffective controls over period end financial disclosure and reporting processes.

Our management believes the material weaknesses identified above led to the restatement of the March 31, 2016 interim financial statements and the December 31, 2015 annual financial statements.We are currently still reviewing our internal controls and procedures related to these material weaknesses and still expect to implement changes in the current fiscal year as resources allow, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to potentially mitigate these material weaknesses.

Our management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

During the quarter ended June 30, 2017, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect the Company's internal control over financial reporting.

On January 9, 2017, the Company issued 300,000 restricted shares and 100,000 warrants to a service provider for consulting services.

On February 22, 2017, the Company issued a total of 207,039 restricted shares of common stock to YMY Industry Ltd., an entity controlled by Zvi Yemini, our Chairman and CEO, 1,035,097 restricted shares of common stock to Marius Nacht and 207,039 restricted shares of common stock to Geliko, LLC for a total consideration of $700,000 or $0.483 per share.

On April 12, 2017, the Company issued a total of 103,520 restricted shares of common stock and issued 15,528 warrants to George Pehlivanian for a total consideration of $50,000 or $0.483 per share.

On April 12, 2017, the Company issued a total of 85,361 restricted shares of common stock to its service providers.

The above-referenced restricted shares were issued without registration under the Securities Act of 1933, as amended (the "Act"), was in reliance upon the exemptions contained in Regulation S promulgated by the United States Securities and Exchange Commission (the "SEC") and Section 4(2) of the Act. The Issuees are not "U.S. Persons," as that term is defined in Rule 902 of Regulation S, and they are "accredited investors," as that term is defined in Rule 501 of Regulation D.

Not applicable.

Not applicable.

By: /s/ Zvi Yemin
Zvi Yemini
Chief Executive Officer and Director
(Principal Executive Officer)
Date: August 7, 2017

By: /s/ Tzahi Geld
Tzahi Geld
Chief Financial Officer
(Principal Financial and Principal Accounting Officer)
Date: August 7, 2017